Physician profile
Vanessa White
NPI 1487219036
$3,364.47
in general payments reported to CMS, 2019-2025
22 companies · $883 in 2025
The $883 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $374 · 2022: $466 · 2023: $475 · 2024: $1,166 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,524.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $525.95 | 2024-2025 | Micra, Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $474.11 | 2022-2025 | Lifevest |
| Inari Medical, INC. | $379.12 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.84 | 2021-2024 | Jardiance |
| Lantheus Medical Imaging, INC. | $252.38 | 2023-2025 | Definity |
| Abiomed | $216.86 | 2024-2025 | Impella |
| Lilly USA, LLC | $203.72 | 2021-2022 | |
| Abbott Laboratories | $170.32 | 2024-2025 | Diamondback Peripheral, Femostop |
| Boston Scientific Corporation | $146.35 | 2023-2024 | Watchman Flx |
| Amgen INC. | $139.28 | 2022-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $126.23 | 2024 | Camzyos |
| Alnylam Pharmaceuticals INC. | $120.36 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $60.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.56 | 2021 | |
| Glaxosmithkline, LLC. | $49.45 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $37.51 | 2022 | |
| Abbvie INC. | $27.69 | 2021 | |
| Genentech USA, INC. | $23.99 | 2022 | |
| Pfizer INC. | $17.07 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.95 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.48 | 2022 | |
| Clarus Therapeutics INC. | $14.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.